BeOne Medicines AG (ONC) P/E Ratio History
Fairly ValuedTrading at 11.8x, near 5Y avg of 12.8x · 50th percentile · In line with own history · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of October 25, 2026, BeOne Medicines AG (ONC) trades at a price-to-earnings ratio of 11.8x, with a stock price of $377.63 and trailing twelve-month earnings per share of $5.66.
The current P/E is roughly in line with its 5-year average of 12.8x. Over the past five years, ONC's P/E has ranged from a low of 3.9x to a high of 26.3x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.3x, ONC trades at a 52% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 159.5x.
Relative to the broader market, ONC trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ONC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ONC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ONC P/E vs Peers
Commercial Specialty Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 19.6 | - | +1747%Best | |
| $15B | 49.1 | 2.14Best | -25% | |
| $3B | 8.6 | - | +68% | |
| $5B | 7.8Lowest | - | +264% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ONC Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $284.97 | $72.28 | 3.9x | -69% |
| FY2026 Q1 | - | $296.97 | $46.47 | 6.4x | -50% |
| FY2025 Q4 | Dec 31 2025 | $303.81 | $21.13 | 14.4x | +13% |
| FY2025 Q3 | - | $340.70 | $12.94 | 26.3x | +106% |
Average P/E for displayed period: 12.8x
ONC Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ONC — Frequently Asked Questions
Quick answers to the most common questions about buying ONC stock.
What is ONC's P/E ratio?
BeOne Medicines AG (ONC) trailing twelve-month P/E ratio is 11.8x, based on TTM diluted EPS of $5.66. The 5-year average P/E is 12.8x and the historical range spans 3.9x to 26.3x.
Is ONC stock overvalued or undervalued?
ONC trades at 11.8x P/E, near its 5-year average of 12.8x. The 50th percentile ranking within the 3.9x–26.3x historical range places valuation within normal bounds.
Is ONC stock expensive?
ONC is fairly valued relative to its own history. The current P/E of 11.8x is near the 5-year average of 12.8x (50th percentile of historical range).
What is ONC's historical P/E range?
Over the past 5 years, ONC's P/E ratio has ranged from 3.9x to 26.3x, with a median of 14.4x and an average of 12.8x. The current P/E of 11.8x places the stock at the 50th percentile of this range. Full historical data spans 2025–2026.
How does ONC's P/E compare to the S&P 500?
ONC trades at 11.8x P/E versus the S&P 500 median of 26.2x. The 55% discount to the market suggests lower growth expectations or perceived higher risk.
How does ONC's valuation compare to Healthcare peers?
BeOne Medicines AG P/E of 11.8x compares to the Healthcare sector median of 24.3x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ONC's PEG ratio?
ONC PEG ratio is N/A, based on a P/E of 11.8x and EPS growth of 624.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ONC's earnings yield?
ONC earnings yield is 8.50%, the inverse of its 11.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.